
Regeneron Pharmaceuticals and Sanofi have announced today positive Phase III trial results investigating the PD-1 inhibitor Libtayo (cemiplimab) in patients …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

